Latest News and Press Releases

Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7

Austin, TX, USA, May 21, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Non-Small-Cell Lung Cancer Drug Market Size, Trends and Insights By Cancer Type...

New Survey Reveals Present-Day Risks of Asbestos Exposure in America

New York, USA, April 19, 2023 (GLOBE NEWSWIRE) -- Mesothelioma Clinical Trials Pipeline Analysis: 50+ Companies are Working to Improve the Treatment Space | DelveInsight The prevalence of...

IND filing followed encouraging preclinical studies conducted in collaboration with Yale Cancer Center that showed a substantial, statistically significant survival benefit when Allocetra™ was...

Poster #1: Tri-specific killer engagers target natural killer cells towards mesotheliomaPoster #2: Enhancing NK cell function in the 'cold' tumor microenvironment of prostate cancer with a novel...

Currently used cisplatin-based combination treatments have limited efficacy against mesothelioma, which is one of the deadliest solid cancers Combining cisplatin with Allocetra™ led to a...

Pharmacodynamic data show comprehensive target engagement after treatment with CPI-0209 monotherapyOral, once-daily 350mg dose selected for Phase 2Enrollment of tumor-specific expansion cohorts is...

OKAYAMA, Japan, Sept. 11, 2019 (GLOBE NEWSWIRE) -- Momotaro-Gene, a clinical-stage biotherapeutics company developing novel gene therapies for the treatment of cancer, today announced the dosing of...

HPN536 is the second TriTAC T cell engager to enter clinical development from the Harpoon pipeline Trial initiated at Sarah Cannon Research Institute in Nashville, Tenn. - a leading drug development...